EMA Authorised: Pombiliti (Cipaglucosidase alfa) — Amicus Therapeutics Europe Limited

View source ↗

Summary

The European Medicines Agency authorised Pombiliti (cipaglucosidase alfa) for Glycogen storage disease type II (Pompe disease) in the European Union. This enzym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glycogen Storage Disease Type Ii

Drugs mentioned

• Pombiliti (Cipaglucosidase alfa)

Snippet

Status: Authorised. Therapeutic area: Glycogen Storage Disease Type II. MAH: Amicus Therapeutics Europe Limited. Decision date: 12/09/2024